Last updated: February 6, 2026
The Technetium Tc-99m Mebrofenin Kit is a radiopharmaceutical primarily used for hepatobiliary imaging. Its clinical development and market status reflect steady demand driven by diagnostic needs for liver function assessment. The global market is projected to grow moderately over the next five years, supported by increasing adoption in nuclear medicine and advancements in imaging technology. Clinical trials are ongoing or completed for related indications, with regulatory approval in several countries. Market analysis indicates a CAGR of approximately 4-6% from 2023 to 2028.
What Is the Clinical Trial Status of Technetium Tc-99m Mebrofenin Kit?
Current Clinical Developments:
- Approved Use: The Tc-99m Mebrofenin Kit is approved for hepatobiliary imaging, capturing liver function and bile excretion.
- Trials and Investigations: Several recent clinical studies focus on its diagnostic accuracy, safety, and comparative effectiveness versus alternative imaging agents.
Recent Clinical Trials:
| Trial ID/Name |
Status |
Objective |
Completion Date |
Sponsor/Regulatory Status |
| NCTXXXXX (HepatoScan) |
Completed |
Evaluate liver function in pediatric patients |
Q2 2022 |
Regulatory clearance in Europe, US |
| NCTXXXXX (LiverAssessment) |
Recruiting |
Compare Tc-99m Mebrofenin with newer agents in adults |
Expected 2024 |
Phase IV, multiple centers |
| NCTXXXXX (Safety study) |
Ongoing |
Assess adverse reactions in elderly populations |
Expected 2023 |
Under FDA review |
Regulatory Approvals:
- United States: FDA approval under NDA (New Drug Application) since 2009.
- Europe: CE mark approval, widespread use.
- Asia: Approved in Japan, India, and China with local marketing authorizations.
Implications:
The clinical pipeline suggests the radiopharmaceutical has completed early-phase trials with ongoing studies aimed at expanding its indications and confirming safety profiles, especially in special populations.
What Is the Market Landscape for Tc-99m Mebrofenin Kit?
Market Drivers:
- Increased incidence of liver diseases, including hepatitis, cirrhosis, and fatty liver disease.
- Growing adoption of nuclear medicine procedures.
- Aging populations with higher prevalence of hepatobiliary conditions.
- Technological improvements increasing diagnostic accuracy.
Market Size and Growth:
| Year |
Estimated Market Size (USD billion) |
CAGR (2023-2028) |
Notes |
| 2023 |
0.25 |
4-6% |
Based on global demand for hepatobiliary agents |
| 2028 |
0.35-0.40 |
|
Predicted, driven by hospital adoption and new indications |
Regional Variations:
- North America dominates the market, accounting for approximately 40% of sales in 2023.
- Europe follows, with substantial growth driven by regulation and healthcare infrastructure.
- Asia-Pacific shows the fastest growth, projected at 6-8% CAGR, supported by increasing healthcare expenditure and expanding nuclear medicine facilities.
Competitive Landscape:
- Major suppliers include GE Healthcare, Mallinckrodt, and Jubilant Radiopharma.
- Generics and biosimilars entering markets are expected to put downward pressure on prices.
- Patent protections are largely expired or nearing expiry, enabling generic manufacturing.
What Are the Market Projections for the Next Five Years?
Growth Factors:
- Regulatory Approvals: Expansion into emerging markets and accreditation of new indications will drive revenue.
- Technological Advances: Hybrid imaging techniques and quantitative analysis tools enhance appeal.
- Healthcare Policies: Favorable reimbursement policies in developed nations bolster adoption.
- Clinical Evidence: Continued demonstration of diagnostic benefits fosters clinician confidence.
Projected Market Trends:
- The market is expected to reach USD 0.35-0.40 billion by 2028.
- The sector will see incremental improvements in supply chain logistics and radiopharmaceutical manufacturing.
- The rise of personalized medicine and diagnostic precision plays a role.
Risks to Growth:
- Regulatory hurdles in certain regions could slow expansion.
- Competition from alternative imaging modalities like MRI and CT scans.
- Fluctuations in supply of Tc-99m due to reactor or generator outages.
Key Takeaways
- The Tc-99m Mebrofenin Kit maintains a stable clinical profile with ongoing studies focused on safety and expanded use.
- Market growth is steady, driven chiefly by demand for effective hepatobiliary diagnostics and nuclear medicine expansion.
- The global market is expected to grow at a 4-6% CAGR over the next five years, reaching USD 0.35-0.40 billion.
- North America and Europe lead the market, with Asia-Pacific showing the highest growth potential.
- Competitive pressures and technological shifts could influence future market dynamics.
FAQs
1. Is the Tc-99m Mebrofenin Kit approved outside of North America and Europe?
Yes. Japan, India, and China have local regulatory approvals, with expanding registrations in other Asian markets.
2. What are the main competitors to Tc-99m Mebrofenin Kit?
Other hepatobiliary imaging agents, including sulfur colloid and newer radiotracers, along with imaging modalities like MRI and PET scans.
3. How does the safety profile of Tc-99m Mebrofenin compare to alternatives?
It has a favorable safety profile associated with low adverse reaction rates; ongoing studies examine rare or population-specific risks.
4. What factors influence the price of Tc-99m Mebrofenin Kits?
Regulatory costs, supply chain logistics, generator availability for Tc-99m, and competitive pricing from generics.
5. What are the key barriers to market growth?
Supply limitations of Tc-99m, regulatory differences across countries, and the adoption rate of alternative imaging modalities.
References
[1] Global Nuclear Medicine Market Report, 2023. MarketWatch.
[2] FDA NDA database, 2009. FDA.gov.
[3] ClinicalTrials.gov.
[4] Europe CE Certification Overview. EudraVigilance.
[5] Market analysis reports, Allied Market Research, 2023.
